HC Wainwright Cuts XOMA (NASDAQ:XOMA) Price Target to $104.00

XOMA (NASDAQ:XOMA) had its target price lowered by HC Wainwright from $123.00 to $104.00 in a report issued on Monday morning,Benzinga reports. The brokerage currently has a buy rating on the biotechnology company’s stock.

Separately, StockNews.com upgraded shares of XOMA from a “sell” rating to a “hold” rating in a research report on Thursday, January 16th.

XOMA Price Performance

Shares of XOMA stock opened at $26.34 on Monday. The company has a market capitalization of $310.36 million, a P/E ratio of -7.57 and a beta of 0.90. The company has a current ratio of 7.52, a quick ratio of 7.52 and a debt-to-equity ratio of 1.28. XOMA has a 12 month low of $19.50 and a 12 month high of $35.00. The stock has a 50 day moving average of $27.42 and a two-hundred day moving average of $28.04.

XOMA (NASDAQ:XOMA) last released its quarterly earnings data on Thursday, November 7th. The biotechnology company reported ($0.39) earnings per share for the quarter, beating the consensus estimate of ($0.44) by $0.05. XOMA had a negative return on equity of 24.95% and a negative net margin of 151.34%. The company had revenue of $7.20 million for the quarter, compared to analyst estimates of $6.66 million. As a group, equities analysts expect that XOMA will post -1.41 EPS for the current year.

Insiders Place Their Bets

In other news, CEO Owen Hughes sold 21,881 shares of the business’s stock in a transaction on Wednesday, November 13th. The stock was sold at an average price of $29.95, for a total transaction of $655,335.95. Following the completion of the sale, the chief executive officer now owns 34,979 shares in the company, valued at $1,047,621.05. The trade was a 38.48 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, major shareholder Bvf Partners L. P/Il sold 500,742 shares of the firm’s stock in a transaction dated Friday, January 24th. The shares were sold at an average price of $26.10, for a total value of $13,069,366.20. The disclosure for this sale can be found here. Insiders own 7.20% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of XOMA. Ellsworth Advisors LLC bought a new stake in shares of XOMA during the third quarter worth approximately $516,000. BNP Paribas Financial Markets raised its position in shares of XOMA by 95.0% during the 3rd quarter. BNP Paribas Financial Markets now owns 1,632 shares of the biotechnology company’s stock valued at $43,000 after acquiring an additional 795 shares during the last quarter. State Street Corp raised its position in shares of XOMA by 1.2% during the 3rd quarter. State Street Corp now owns 142,857 shares of the biotechnology company’s stock valued at $3,783,000 after acquiring an additional 1,754 shares during the last quarter. Barclays PLC lifted its stake in shares of XOMA by 300.7% in the 3rd quarter. Barclays PLC now owns 11,256 shares of the biotechnology company’s stock valued at $298,000 after purchasing an additional 8,447 shares during the period. Finally, Geode Capital Management LLC boosted its position in shares of XOMA by 0.6% in the 3rd quarter. Geode Capital Management LLC now owns 182,741 shares of the biotechnology company’s stock worth $4,840,000 after purchasing an additional 1,138 shares during the last quarter. Institutional investors own 95.92% of the company’s stock.

About XOMA

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.